Insmed’s iPlex Gets Updated User Fee Date Of Dec. 12
This article was originally published in The Pink Sheet Daily
Executive Summary
Insmed's NDA for the growth therapy iPlex (mecasermin rinfibate) has an updated user fee date of Dec. 12, the firm announced Oct. 25
You may also be interested in...
Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open
Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.
Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity
The company plans to launch the extreme short stature therapy in January with a 30-member sales force.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.